Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C.

To investigate the relationship among circulating cytokines, inflammation in the liver, and kind of response to interferon-alpha (IFN-alpha) in hepatitis C, we studied 63 consecutive patients (38 male, 25 female), treated with IFN for up to 1 year. Serum tumor necrosis factor-alpha (TNF-alpha) was measured at baseline and after 3 months of treatment. Transient (TR) or sustained response (SR) was observed in 29 and 16 patients, respectively. Baseline levels of TNF < or = 22 ng/L were observed in 69% of patients with SR, 55% of patients with TR, and 22% of nonresponders (p < 0.01). There was a significant correlation between baseline TNF levels and histologic grading score of hepatitis (p < 0.01). After 3 months of treatment, TNF levels >22 ng/L were observed in 63% of patients with SR, 69% of patients with TR, and 83% of nonresponders (p NS). Independent of the treatment outcome, TNF levels were lower at baseline and increased significantly with treatment in patients with lower histologic grading (p < 0.005). In conclusion, in patients with chronic hepatitis C, circulating TNF levels correlate with the degree of inflammation in the liver. Response to IFN is accompanied by an inflammatory response involving the release of TNF.

[1]  F. Chisari.  Hepatitis B virus transgenic mice: Insights into the virus and the disease , 1995, Hepatology.

[2]  P. Marcellin,et al.  Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. , 1999, Journal of hepatology.

[3]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[4]  M. Pirisi,et al.  Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[5]  Y. Matsuzawa,et al.  Induction of interleukin‐6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C , 1996, Hepatology.

[6]  L. Corey,et al.  Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. , 1994, The Journal of infectious diseases.

[7]  G. Alexander,et al.  Spontaneous production of tumour necrosis factor α and interleukin-1β during interferon-α treatment of chronic HBV infection , 1990, The Lancet.

[8]  F. Baralle,et al.  Discordant results from hepatitis C virus genotyping by procedures based on amplification of different genomic regions , 1996, Journal of clinical microbiology.

[9]  R. Gish,et al.  Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre‐ and posttreatment with interferon alfa , 1996, Hepatology.

[10]  Fabris,et al.  Kinetics of serum soluble tumour necrosis factor receptor (TNF‐R) type‐I and type‐II after a single interferon‐alpha (IFN‐α) injection in chronic hepatitis C , 1999, Clinical and experimental immunology.

[11]  M. Alter,et al.  Epidemiology of Hepatitis C in the West , 1995, Seminars in liver disease.

[12]  K. Lindsay.  Therapy of hepatitis C: Overview , 1997, Hepatology.

[13]  P. Jouet,et al.  Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C. , 1994, Gastroenterology.

[14]  A. Neumann,et al.  Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.

[15]  G. Davis,et al.  Factors predictive of a beneficial response to therapy of hepatitis C , 1997, Hepatology.

[16]  F. Chisari,et al.  To kill or to cure: options in host defense against viral infection. , 1996, Current opinion in immunology.

[17]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[18]  J. Hoofnagle,et al.  Therapy of Hepatitis C , 1995, Seminars in liver disease.

[19]  W. Jelkmann,et al.  Serum erythropoietin and interleukin-6 levels in hemodialysis patients with hepatitis virus infection. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[20]  G. Alexander,et al.  In vitro effects of lymphoblastoid interferon on lymphocyte activation and cell-mediated cytolysis in patients with chronic hepatitis B virus infection. , 1986, Journal of hepatology.

[21]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[22]  H. Tilg,et al.  Serum levels of cytokines in chronic liver diseases. , 1992, Gastroenterology.

[23]  J. Schmidt,et al.  Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo , 1996, Hepatology.